ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Aduro Biotech Inc

Aduro Biotech Inc (ADRO)

14.595
0.00
(0.00%)
Al cierre: 05 Febrero 3:00PM
14.595
0.00
( 0.00% )
Fuera de horario: -

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
14.595
Postura de Compra
14.60
Postura de Venta
17.00
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Precio Anterior
14.595
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen promedio (3 m)
-
Volumen financiero
-
Precio Promedio Ponderado
-

ADRO Últimas noticias

Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing

Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE...

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical...

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results

BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation...

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of dosesPharmacokinetics (PK) of BION-1301...

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company...

Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress

BERKELEY, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

BERKELEY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of...

Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference

BERKELEY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is...

Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference

BERKELEY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ADRO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Aduro Biotech?
El precio actual de las acciones de Aduro Biotech es US$ 14.595
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Aduro Biotech?
Aduro Biotech ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SBETSharpLink Gaming Inc
US$ 0.6277
(49.45%)
3.64M
RANIRani Therapeutics Holdings Inc
US$ 2.08
(44.44%)
9.53M
IVVDInvivyd Inc
US$ 2.9098
(37.91%)
10.44M
APPSDigital Turbine Inc
US$ 3.29
(29.53%)
4.52M
DGLYDigital Ally Inc
US$ 0.2468
(16.42%)
5.31M
KTTAPasithea Therapeutics Corporation
US$ 1.89
(-31.02%)
1.19M
FORMFormFactor Inc
US$ 30.27
(-26.39%)
128.12k
AVGRAvinger Inc
US$ 0.42
(-24.99%)
229.64k
PIImpinj Inc
US$ 96.00
(-24.45%)
243.57k
SWKSSkyworks Solutions Inc
US$ 67.2359
(-22.79%)
1.29M
IVVDInvivyd Inc
US$ 2.9098
(37.91%)
10.44M
RIMEAlgorhythm Holdings Inc
US$ 0.0208
(-0.48%)
9.79M
RANIRani Therapeutics Holdings Inc
US$ 2.08
(44.44%)
9.53M
CYNCYNGN Inc
US$ 0.0838
(2.20%)
8.61M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.052
(0.00%)
6.6M

ADRO Discussion

Ver más
nferna nferna 2 años hace
Nice run from 18 to 22 these past two weeks
👍️0
k9narc k9narc 4 años hace
Symbol will be changing from ADRO to KDNY
👍️0
k9narc k9narc 4 años hace
I expect it to, but that may be "hope" talking.

I bought while stoned...fat fingered the number of shares, so ended up with a pile. Averaged at 13.30/shr after split and am looking for 20.

Good luck.
👍️0
Newc Newc 4 años hace
do you think this may go up some with the merger?
👍️0
k9narc k9narc 4 años hace
The closing of the merger is anticipated to take place on or around October 5, 2020. Following closing of the merger, the combined company will be renamed Chinook Therapeutics and trade under the trading symbol “KDNY.”
👍️0
k9narc k9narc 4 años hace
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics....


https://www.globenewswire.com/news-release/2020/10/01/2102576/0/en/Aduro-Biotech-Stockholders-Approve-Merger-Agreement-with-Chinook-Therapeutics.html
👍️0
k9narc k9narc 4 años hace
That was fun.... wake up to a 400%+ gainer and find out a R/S was the cause. I forgot that was coming. I guess we get our new ticker Monday.
👍️0
k9narc k9narc 4 años hace
It was fun to watch today... up even more after hours.
👍️0
Newc Newc 4 años hace
Ill be watching tomorrow.
👍️0
k9narc k9narc 5 años hace
Seems investors don't like the upcoming merger....

"– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

– Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors"

https://www.globenewswire.com/news-release/2020/06/02/2042120/0/en/Aduro-Biotech-and-Chinook-Therapeutics-Announce-Definitive-Merger-Agreement.html

👍️0
beebread beebread 5 años hace
my thoughts: going higher
👍️0
k9narc k9narc 5 años hace
Any thoughts on the 20%+ bounce on this today, or am I the only nut playing this?

CBOE BZX REAL-TIME LAST SALE
2.79 USD

TODAY'S CHANGE
+0.51increase +22.37%increase

VOLUME
982,159

PRICE QUOTE AS OF
13:41 ET
👍️0
k9narc k9narc 5 años hace
Any thoughts on the merger?
👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-14-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-13-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-05-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Stockslayr Stockslayr 5 años hace
Gandalf standing at the $2 resistance
👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 02-03-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Stockslayr Stockslayr 5 años hace
Near the HOD. How about 2 bones tomorrow??
👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
makinezmoney makinezmoney 5 años hace
$ADRO: Wow.... $7price target


SVB Leerink just raised it from $3 target


Buy all you can here at $1.63


And don't hold back.


This could really go.


I'm in for sure !



GO $ADRO
👍️0
ClayTrader ClayTrader 5 años hace
* * $ADRO Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
Honolulu Trader Honolulu Trader 5 años hace
1.05

1/2
👍️0
PennyStock Alert PennyStock Alert 5 años hace
They stole ADXS's crumbs and now are reeling from the disaster!
👍️0
willlbone willlbone 6 años hace
Phase 1b Stung.
👍️0
jondoeuk jondoeuk 6 años hace
ASCO title https://meetinglibrary.asco.org/record/172413/abstract
👍️0
strongstock strongstock 6 años hace
Rated strong buy- could see some volume soon...

https://finance.yahoo.com/news/aduro-biotech-adro-upgraded-strong-140902253.html
👍️0
10bags 10bags 6 años hace
ADRO ready for a 50%+ move
Big partners

Elly lilly
Novartis
Merck

Milestone payments

3.30 cash per share
2.00 book value.

Chart set up for a move
👍️0
jondoeuk jondoeuk 6 años hace
A new preclinical paper https://www.cell.com/cell-reports/fulltext/S2211-1247(18)31810-2
👍️0
ClayTrader ClayTrader 6 años hace
* * $ADRO Video Chart 12-19-18 * *

Link to Video - click here to watch the technical chart video

👍️0
@LiftedCapital @LiftedCapital 6 años hace
LOOKS LIKE I WILL BE TWERKING... ALL THE WAY TO THE BANK -->>
👍️0
@LiftedCapital @LiftedCapital 6 años hace
N thats how you take care of business!!! Yeall have a nice day!!!
👍️0
@LiftedCapital @LiftedCapital 6 años hace
FROM HERE ON OUT $HIT BE FADING AWAY!!! $$$$$$$ -->>

IM SO FUC.ING TIT$

👍️0
@LiftedCapital @LiftedCapital 6 años hace
IM SOOOOO DRIPPIE -->>
👍️0
@LiftedCapital @LiftedCapital 6 años hace
WHO THE F... IS GONNA STEPUP??? NOONE!!! IM THE BEST WATCH ME FLEX THIS SHORT GAME EVERY DAY PLAYAZ!!!
👍️0
@LiftedCapital @LiftedCapital 6 años hace
I AM UNLIMITED!!! AINT NOBODY BETTA DEN ME!!! BUT AT LEAST YOU CAN GET A TASTE -->>
👍️0
@LiftedCapital @LiftedCapital 6 años hace
SHORT ADRO $3.15
👍️0
jondoeuk jondoeuk 6 años hace
Here is another http://www.codiakbio.com/press-releases/codiak-biosciences-presents-first-data-on-exosting-a-novel-engineered-exosome-therapeutic-targeting-checkpoint-refractory-tumors-at-the-society-for-immunotherapy-of-cancers-33rd-ann/
👍️0
jondoeuk jondoeuk 6 años hace
In one interview Dr. Jaffee said a pilot trial investigating a neoantigen vaccine (synthetic long peptides plus STING adjuvant), anti-OX40 and anti-PD-1 will take place in patients with MSS CRC and mPADC. Here is the preclinical study https://insight.jci.org/articles/view/122857
👍️0
jondoeuk jondoeuk 6 años hace
Dr. Luke presented data on $BMY's STING agonist [1] as well as one by $SBPH [2] and Actym Therapeutics [3].

1 https://pbs.twimg.com/media/DtUqr7-WsAAkxFv.jpg
2 https://pbs.twimg.com/media/DtUqr7_WkAEWxuN.jpg
3 https://pbs.twimg.com/media/DtUqr8DWwAAlai1.jpg
👍️0
jondoeuk jondoeuk 6 años hace
Most had failed a number of lines of therapy and over 46% had treatment with a checkpoint inhibitor. So you shouldn't expect to see much evidence for efficacy in a PhIa trial. The main purpose of these is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a drug.
👍️0
XXSPOWER XXSPOWER 6 años hace
what about the 35 out of 41 (85%) pts that stopped treatment STING SINGLE AGENT
👍️0
jondoeuk jondoeuk 6 años hace
SITC abstract https://pbs.twimg.com/media/DrUnGSyXcAA6Wvh.jpg

The company will host and webcast an investor event on Friday, November 9, 2018 at 6:30 p.m. Eastern Time in Washington, D.C.
👍️0
jondoeuk jondoeuk 6 años hace
It should activate the pathway in multiple cells in the TME (including macrophages and ECs to name of few). The innate response is via neutrophils after TNFa has caused hemorrhagic necrosis. Adaptive response is dependent on STING and IFNB activation in DCs. Abscopal effects through polyfunctional antigen specific T-cells.
👍️0
Murph1953 Murph1953 6 años hace
Does ADRO's STING stimulate the same immune cells as AFMD's NK, Natural Killer cells, or does ADRO stimulate T-cells(which kill) and B-cells(which produce antibodies)?

Would really appreciate your answer.

Thanks
👍️0
jondoeuk jondoeuk 6 años hace
Personalised LADD won't be moving forward after the current PhI is completed. The company now looks to licence it.
👍️0
jondoeuk jondoeuk 6 años hace
$JNJ has terminated the exclusive global license agreement to develop ADU-214, ADU-741 and GVAX Prostate for all indications. From the wording I don't hold out much hope for pLADD.

https://www.sec.gov/Archives/edgar/data/1435049/000119312518289503/d619516d8k.htm
👍️0
CATTDOGG12347 CATTDOGG12347 6 años hace
I will no longer buy Advaxis common stock and I will not recommend it to anybody I like. I will however continue to hold my shares and vote NO to everything management wants until they sell the company.
Anybody who does their job with such ineptitude as the BOD and management of this company doesn’t deserve to have a job.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock